Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 113, Issue 49, Pages 14115-14120Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1608520113
Keywords
mast cell; allergy; IgE receptor; oligonucleotides; dermatitis
Categories
Funding
- Division of Intramural Research of National Institute of Allergy and Infectious Diseases and National Heart, Lung, and Blood Institute within the NIH
Ask authors/readers for more resources
Allergic diseases are driven by activation of mast cells and release of mediators in response to IgE-directed antigens. However, there are no drugs currently available that can specifically down-regulate mast cell function in vivo when chronically administered. Here, we describe an innovative approach for targeting mast cells in vitro and in vivo using antisense oligonucleotide-mediated exon skipping of the beta-subunit of the high-affinity IgE receptor (Fc epsilon RI beta) to eliminate surface high-affinity IgE receptor (Fc epsilon RI) expression and function, rendering mast cells unresponsive to IgE-mediated activation. As Fc epsilon RI beta expression is restricted to mast cells and basophils, this approach would selectively target these cell types. Given the success of exon skipping in clinical trials to treat genetic diseases such as Duchenne muscular dystrophy, we propose that exon skipping of Fc epsilon RI beta is a potential approach for mast cell-specific treatment of allergic diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available